NCT06800196View on ClinicalTrials.gov

A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Solid Tumors with FGFR2 Alterations, Adult
Interventions
DRUG

KNT-0916

• KNT-0916 is an oral inhibitor of FGFR2.

Sponsors
All Listed Sponsors
lead

KinoTeck Therapeutics Co., Ltd

INDUSTRY

NCT06800196 - A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations | Biotech Hunter | Biotech Hunter